Frontiers in the Pathology and Pathogenesis of Ovarian Cancer

Thing Rinda Soong, T. Rinda Soong, Daniela M Dinulescu, Wa Xian, Christopher P Crum
Hematology/oncology clinics of North America · 2018 · vol. 32(6) , pp. 915–928 · doi:10.1016/j.hoc.2018.07.013 · PMID:30390765 · W2899258719
review OA: closed CC0
Limited metadata. Only one source feed has indexed this record so far — no abstract, full text, or open-access copy is available through Endo Lab. The publisher's page (linked below) is the canonical location for the actual content. If you have institutional access, use "Find at my library".
View at publisher → View on OpenAlex View on PubMed
⚙ AI-generated summary by claude@2026-06, 2026-06-07 ⓘ

This review discusses recent advancements in understanding the pathological features and underlying mechanisms of ovarian cancer development.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

My notes (saved in your browser only)

MeSH descriptors

Cystadenocarcinoma, Serous Cystadenocarcinoma, Serous Cystadenocarcinoma, Serous Cystadenocarcinoma, Serous Fallopian Tube Neoplasms Fallopian Tube Neoplasms Fallopian Tube Neoplasms Fallopian Tube Neoplasms Neoplastic Stem Cells Neoplastic Stem Cells Neoplastic Stem Cells Neoplastic Stem Cells Ovarian Neoplasms Ovarian Neoplasms Ovarian Neoplasms Ovarian Neoplasms Tumor Escape Female Humans Tumor Escape

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (72)

Source provenance

europepmc
last seen: 2026-06-04T01:30:01.192114+00:00
openalex
last seen: 2026-06-04T00:00:01.174412+00:00
pubmed
last seen: 2026-05-13T22:19:25.021412+00:00
License: CC0 · commercial use OK